Citations

Showing 10 of 108119 citations.

Epidemiology and outcomes of pulmonary hypertension in the cardiac intensive care unit
Jentzer, Jacob C. , Wiley, Brandon M. , Reddy, Yogesh N.V. , Solomon, Michael A. , Solomon, Michael A , Nishimura, Rick , Jentzer, Jacob C , Barnett, Christopher F. , Borlaug, Barry A.

Mayo Clinic

European Heart Journal. Acute Cardiovascular Care | December 22, 2021 | Volume: 11 | Issue: 3 | Pages: 230-241

10.1093/ehjacc/zuab127 | PMID 35064269 Get It

Abstract Aims Pulmonary hypertension (PH) has been consistently associated with adverse outcomes in hospitalized patients. Limited epidemiologic data exist regarding PH in the cardiac intensive care unit (CICU) population. Here, we describe the prevalence, aetiology, and outcomes of PH in the CICU. Methods and results Cardiac intensive care unit patients admitted from 2007 to 2018 who had right ventricular systolic pressure (RVSP) measured via transthoracic echocardiography near CICU admission were included. PH was defined as RVSP >35 mmHg, and moderate-to-severe PH as RVSP ≥50 mmHg. Predictors of in-hospital mortality were determined using multivariable logistic regression. Among 5042 patients (mean age 69.4 ± 14.8 years; 41% females), PH was present in 3085 (61%). The majority (68%) of patients with PH had left heart failure, and 29% had lung disease. In-hospital mortality occurred in 8.3% and was more frequent in patients with PH [10.9% vs. 4.2%, adjusted odds ratio (OR) 1.40, 95% confidence interval (CI) 1.03–1.92, P = 0.03], particularly patients with moderate-to-severe PH (14.4% vs. 6.2%, adjusted OR 1.65, 95% CI 1.27–2.14, P < 0.001). In-hospital mortality increased incrementally as a function of higher RVSP (adjusted 1.18 per 10 mmHg increase, 95% CI 1.09–1.28, P < 0.001). Patients with higher RVSP or moderate-to-severe PH had increased in-hospital mortality across admission diagnoses (all P < 0.05). Conclusions Pulmonary hypertension is very common in the CICU population and appears to be independently associated with a higher risk of death during hospitalization, although the strength of this association varies according to the underlying admission diagnosis. These data highlight the importance of PH in patients with cardiac critical illness.
TANGO2 Mutation: A Genetic Cause of Multifocal Combined Dystonia
Frey, Jessica , Burns, Matthew R. , Chiu, Shannon , Shukla, Aparna Wagle, Kouzi, Ahmad El, Jackson, Jessica L. , Arn, Pamela , Elkouzi, Ahmad , El Kouzi, Ahmad , Jackson, Jessica, Malaty, Irene A , Shukla, Aparna Wagle , Malaty, Irene A.

Mayo Clinic

Movement Disorders Clinical Practice | December 22, 2021 | Volume: 9 | Issue: 3 | Pages: 380-382

10.1002/mdc3.13400 | PMID 35402644 Get It

Same-session salvage endoscopic submucosal dissection for an incompletely resected rectal neuroendocrine tumor
Garimella, Vishal, Chandrasekhara, Vinay

Mayo Clinic

Endoscopy | December 21, 2021 | Volume: 54 | Issue: 10 | Pages: E598-E599

10.1055/a-1694-3367 | PMID 34933363 Get It

Increased Risk for Maternal Anxiety during the COVID-19 Outbreak in Brazil among Pregnant Women without Comorbidities
Nomura, Roseli Mieko Yamamoto , Ubinha, Ana Carla Franco , Tavares, Isabela de Paula , Costa, Maria Laura , Opperman, Maria Lucia da Rocha, Brock, M. , Trapani, Alberto , Damásio, Lia Cruz Vaz da Costa , Reis, Nadia Stella Viegas , Borges, Vera Therezinha Medeiros , Araújo, Ana Cristina Pinheiro Fernandes de , Opperman, Maria Lucia , Brock, Marianna Facchinetti , Zaconeta, Alberto , Araujo, Ana Cristina Pinheiro Fernandes de , Ruano, Rodrigo , Nomura, Roseli , Trapani, Alberto , Damasio, Lia , Borges, Vera , Opperman, Maria Lúcia, Ruano, Rodrigo

Mayo Clinic

Revista Brasileira de Ginecologia e Obstetrícia / RBGO Gynecology and Obstetrics | December 21, 2021 | Volume: 43 | Issue: 12 | Pages: 932-939

10.1055/s-0041-1740234 | PMID 34933387 Get It

Abstract Objective To study maternal anxiety in pregnant women without comorbidities in the context of the COVID-19 outbreak in Brazil and to study maternal knowledge and concerns about the pandemic. Methods This is a secondary analysis from a national multicenter cross-sectional study performed in 10 cities, from June to August, 2020, in Brazil. Interviewed postpartum women, without medical or obstetrical comorbidities, were included in the present subanalysis. A structured questionnaire and the Beck Anxiety Inventory (BAI) were applied. Results Out of the 1,662 women, 763 (45.9%) met the criteria for the current analysis and 16.1% presented with moderate and 11.5% with severe maternal anxiety. Moderate or severe maternal anxiety was associated with high school education (odds ratio [OR]:1.58; 95% confidence interval [CI]:1.04–2.40). The protective factor was cohabiting with a partner (OR: 0.46; 95%CI: 0.29–0.73). There was a positive correlation between the total BAI score and receiving information about care in the pandemic (rpartial 0.15; p < 0.001); concern about vertical transmission of COVID-19 (rpartial 0.10; p = 0.01); receiving information about breastfeeding (rpartial 0.08; p = 0.03); concerns about prenatal care (rpartial 0.10; p = 0.01), and concerns about the baby contracting COVID-19 (rpartial 0.11; p = 0.004). The correlation was negative in the following aspects: self-confidence in protecting from COVID-19 (rpartial 0.08; p = 0.04), having learned (rpartial 0.09; p = 0.01) and self-confidence in breastfeeding (rpartial 0.22; p < 0.001) in the context of the pandemic. Conclusion The anxiety of pregnant women without medical or obstetrical comorbidities was associated to high school educational level and not living with a partner during the COVID-19 pandemic. Self-confidence in protecting against COVID-19 and knowledge about breastfeeding care during the pandemic reduced maternal anxiety.
A Blinded Randomized Trial Comparing Standard Activated Clotting Time Heparin Management to High Target Active Clotting Time and Individualized Hepcon HMS Heparin Management in Cardiopulmonary Bypass Cardiac Surgical Patients
Nuttall, Gregory A. , Christensen, Jon M. , Santrach, Paula J., Smith, Mark M. , Smith, Bradford B. , Schaff, Hartzell V.

Mayo Clinic

Annals of Thoracic and Cardiovascular Surgery | December 21, 2021 | Volume: 28 | Issue: 3 | Pages: 204-213

10.5761/atcs.oa.21-00222 | PMID 34937821 Get It

The MDM2 antagonist idasanutlin in patients with polycythemia vera: results from a single-arm phase 2 study
Mascarenhas, John , Passamonti, Francesco , Burbury, Kate , El‐Galaly, Tarec Christoffer , Gerds, Aaron T. , Gupta, Vikas , Higgins, Brian , Wonde, Kathrin, Jamois, Candice , Kovic, Bruno, Huw, Ling‐Yuh, Katakam, Sudhakar Babu, Maffioli, Margherita , Palmer, Jeanne , Bellini, Marta, Yacoub, Abdulraheem , Gerds, Aaron T , Mesa, Ruben , Ross, David M , Vannucchi, Alessandro M , Yacoub, Abdulraheem , Mascarenhas, John , Gupta, Vikas , Passamonti, Francesco , El-Galaly, Tarec C , Mesa, Ruben A. , Vannucchi, Alessandro M.

Mayo Clinic

Blood Advances | December 21, 2021 | Volume: 6 | Issue: 4 | Pages: 1162-1174

10.1182/bloodadvances.2021006043 | PMID 34933330 Get It

Abstract Idasanutlin, an MDM2 antagonist, showed clinical activity and a rapid reduction in JAK2 V617F allele burden in patients with polycythemia vera (PV) in a phase 1 study. This open-label phase 2 study evaluated idasanutlin in patients with hydroxyurea (HU)-resistant/-intolerant PV, per the European LeukemiaNet criteria, and phlebotomy dependence; prior ruxolitinib exposure was permitted. Idasanutlin was administered once daily on days 1 through 5 of each 28-day cycle. The primary end point was composite response (hematocrit control and spleen volume reduction &gt; 35%) in patients with splenomegaly and hematocrit control in patients without splenomegaly at week 32. Key secondary end points included safety, complete hematologic response (CHR), patient-reported outcomes, and molecular responses. All patients (n = 27) received idasanutlin; 16 had response assessment (week 32). Among responders with baseline splenomegaly (n = 13), 9 (69%) attained any spleen volume reduction, and 1 achieved composite response. Nine patients (56%) achieved hematocrit control, and 8 patients (50%) achieved CHR. Overall, 43% of evaluable patients (6/14) showed a ≥50% reduction in the Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (week 32). Nausea (93%), diarrhea (78%), and vomiting (41%) were the most common adverse events, with grade ≥ 3 nausea or vomiting experienced by 3 patients (11%) and 1 patient (4%), respectively. Reduced JAK2 V617F allele burden occurred early (after 3 cycles), with a median reduction of 76%, and was associated with achieving CHR and hematocrit control. Overall, the idasanutlin dosing regimen showed clinical activity and rapidly reduced JAK2 allele burden in patients with HU-resistant/- intolerant PV but was associated with low-grade gastrointestinal toxicity, leading to poor long-term tolerability. This trial was registered at www.clinincaltrials.gov as #NCT03287245.
Breakthrough COVID‐19 after SARS‐CoV‐2 vaccination in solid organ transplant recipients: An analysis of symptomatic cases and monoclonal antibody therapy
Bhaimia, Eric , Bierle, Dennis M. , Yetmar, Zachary A. , Ganesh, Ravindra , Razonable, Raymund R.

Mayo Clinic

Transplant Infectious Disease | December 21, 2021 | Volume: 24 | Issue: 2 | Pages: No page available

10.1111/tid.13779 | PMID 34932874 Get It

AbstractBackgroundSolid organ transplant (SOT) recipients are at increased risk for complications from SARS‐CoV‐2 infection. Little is known regarding clinical course and outcomes of breakthrough COVID‐19 in the fully vaccinated SOT population. We sought to describe our cohort of SOT recipients who developed symptomatic breakthrough COVID‐19 after full vaccination.MethodsWe conducted a retrospective review of SOT recipients diagnosed with COVID‐19 at least 14 days after completing SARS‐CoV‐2 vaccination. Patients were analyzed according to those presenting with mild‐to‐moderate and severe COVID‐19, respectively. We described presenting characteristics, COVID‐19 therapy, and analyzed outcomes including emergency department (ED) visits, hospitalization, and intensive care unit (ICU) admission.ResultsThirty‐five patients met inclusion criteria. These had a mean age of 60.8 years and kidney transplant was the most common SOT type. Five patients presented with severe COVID‐19 at diagnosis, all requiring hospitalization without ICU admission. From the 30 patients who presented with mild‐to‐moderate infection, 28 received casirivimab–imdevimab. Four of these 28 (14.3%) had an ED visit, with one requiring hospital admission (3.4%). No patients required ICU admission.ConclusionBreakthrough COVID‐19 may occur in SOT recipients after full vaccination, though they appear to have acceptable outcomes. Anti‐spike monoclonal antibody therapy for eligible SOT patients may have mitigated clinical progression and improved the outcomes. Further study with large cohorts is warranted.
BPNSTs: In the eye of the beholder
Kaufmann, Timothy J. , Kaufmann, Timothy J , Erickson, Bradley J.

Mayo Clinic

Neuro-Oncology | December 21, 2021 | Volume: 24 | Issue: 4 | Pages: 610-611

10.1093/neuonc/noab296 | PMID 35029678 Get It

The year in cardiovascular medicine 2021: cardio-oncology
Herrmann, Joerg , López‐Fernández, Teresa , Lyon, Alexander R. , López-Fernández, Teresa , Lyon, Alexander R

Mayo Clinic

European Heart Journal | December 21, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/eurheartj/ehab891 | PMID 34974609 Get It